The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients-Reference-Cited by-同舟云学术

The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Published:2018-03-28 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Schneider Christopher,Wallner Markus,Kolesnik Ewald,Herbst Viktoria,Mächler Heinrich,Pichler Martin,von Lewinski Dirk,Sedej Simon^ORCID,Rainer Peter P.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-23630-w.pdf

Reference36 articles.

1. Moslehi, J. J. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 375, 1457–1467, https://doi.org/10.1056/NEJMra1100265 (2016).

2. Zamorano, J. L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37, 2768–2801, https://doi.org/10.1093/eurheartj/ehw211 (2016).

3. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031–1037, https://doi.org/10.1056/NEJM200104053441401 (2001).

4. Sherbenou, D. W. & Druker, B. J. Applying the discovery of the Philadelphia chromosome. J Clin Invest 117, 2067–2074, https://doi.org/10.1172/JCI31988 (2007).

5. Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36, 422–439, https://doi.org/10.1016/j.tips.2015.04.005 (2015).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A fatal case of cabozantinib-induced cardiomyopathy;Future Cardiology;2024-08-05

2. Sodium‐Glucose Co‐Transporter‐2 Inhibitor Empagliflozin Attenuates Sorafenib‐Induced Myocardial Inflammation and Toxicity;Environmental Toxicology;2024-06-17

3. Proposal for considerations during human iPSC-derived cardiac organoid generation for cardiotoxicity drug testing;Biomedicine & Pharmacotherapy;2024-05

4. Sorafenib induces muscle wasting by disrupting the activity of distinct chromatin regulators;2024-01-04

5. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07